HULUWA(SH:605199) Ge Long Hui A P P·2025-09-01 09:20Core Viewpoint - ST HuLuWa (605199.SH) has received approval from the National Medical Products Administration for the registration of two pharmaceutical products, indicating a significant advancement in its product pipeline and potential market opportunities in diabetes treatment [1] Group 1: Product Approval - The company has been granted a drug registration certificate for Metformin and Empagliflozin Tablets (I) and an inhalation solution of Compound Ipratropium Bromide, which reflects the company's commitment to expanding its therapeutic offerings [1] - Metformin and Empagliflozin Tablets (I) are indicated for use in conjunction with diet and exercise to improve blood sugar control in adult patients with type 2 diabetes who are already receiving treatment with Empagliflozin and Metformin Hydrochloride [1] - The approval was based on the evaluation of quality and efficacy consistent with the reference preparation, highlighting the company's adherence to regulatory standards [1]